新教条还是旧教条？
New dogmas or old?
作者信息
Whittle B J R
机构信息
William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine, Charterhouse Square, London EC1M 6BQ, UK.
出版信息
Gut. 2003 Sep;52(9):1379-81. doi: 10.1136/gut.52.9.1379.
Abstract
Recent experimental studies may undermine our understanding of the gastrointestinal side effects of non-steroidal anti-inflammatory drugs and cast a shadow on the original concept that underpins the development of the recent addition to the clinical anti-inflammatory armamentarium, the COX-2 selective inhibitors. But is this just a passing cloud or a total eclipse of the COX theory?
摘要
近期的实验研究可能会削弱我们对非甾体抗炎药胃肠道副作用的理解，并给支撑临床抗炎药物新成员——COX-2选择性抑制剂研发的原有概念蒙上阴影。但这只是暂时的阴霾，还是COX理论的彻底覆灭呢？
相似文献
1
New dogmas or old?新教条还是旧教条？
Gut. 2003 Sep;52(9):1379-81. doi: 10.1136/gut.52.9.1379.
2
NSAIDs: the emperor's new dogma?非甾体抗炎药：皇帝的新教条？
Gut. 2003 Sep;52(9):1376-8. doi: 10.1136/gut.52.9.1376.
3
Cox-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly.环氧化酶-2抑制剂及其他非甾体抗炎药用于治疗老年人疼痛
Clin Geriatr Med. 2001 Aug;17(3):489-502, vi. doi: 10.1016/s0749-0690(05)70082-3.
4
Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?环氧化酶-2抑制剂是否能提供与传统非甾体抗炎药类似的益处，同时胃肠道毒性更低？
Ann Intern Med. 2000 Jan 18;132(2):134-43. doi: 10.7326/0003-4819-132-2-200001180-00008.
5
[Selective COX-2 non-steroidal anti-inflammatory agents and gastrointestinal toxicity].[选择性环氧化酶-2非甾体抗炎药与胃肠道毒性]
Rev Esp Enferm Dig. 2001 Dec;93(12):819-20.
6
Cyclooxygenase 2 selective agents and upper gastrointestinal disease.环氧化酶2选择性药物与上消化道疾病
JAMA. 2000 Apr 19;283(15):1961; author reply 1962.
7
Cyclooxygenase 2 selective agents and upper gastrointestinal disease.环氧化酶2选择性药物与上消化道疾病
JAMA. 2000 Apr 19;283(15):1961-2.
8
COX-2 inhibitors. What is their place?环氧化酶-2抑制剂。它们的地位如何？
Aust Fam Physician. 2000 Sep;29(9):847-52.
9
NSAIDs: gastroprotection or selective COX-2 inhibitors?
Palliat Med. 2005 Mar;19(2):165; author reply 166-7. doi: 10.1191/0269216305pm991xx.
10
The coxibs, selective inhibitors of cyclooxygenase-2.昔布类药物，即环氧化酶-2的选择性抑制剂。
N Engl J Med. 2001 Aug 9;345(6):433-42. doi: 10.1056/NEJM200108093450607.
引用本文的文献
1
Strictures, diaphragms, erosions or ulcerations of ischemic type in the colon should always prompt consideration of nonsteroidal anti-inflammatory drug-induced lesions.结肠中出现的狭窄、隔膜、缺血型糜烂或溃疡，应始终促使人们考虑非甾体抗炎药引起的病变。
World J Gastroenterol. 2005 Oct 7;11(37):5828-33. doi: 10.3748/wjg.v11.i37.5828.
本文引用的文献
1
2
GASTRIC MUCOSAL INJURY BY FATTY AND ACETYLSALICYLIC ACIDS.脂肪酸和乙酰水杨酸所致的胃黏膜损伤
Gastroenterology. 1964 Mar;46:245-53.
3
Ability of some antirheumatic drugs to uncouple oxidative phosphorylation.某些抗风湿药物解偶联氧化磷酸化的能力。
Nature. 1962 Dec 29;196:1323-4. doi: 10.1038/1961323a0.
4
NSAIDs: the emperor's new dogma?非甾体抗炎药：皇帝的新教条？
Gut. 2003 Sep;52(9):1376-8. doi: 10.1136/gut.52.9.1376.
5
6
Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.非甾体抗炎药：总体风险与管理。环氧化酶-2抑制剂和质子泵抑制剂的互补作用。
Gut. 2003 Apr;52(4):600-8. doi: 10.1136/gut.52.4.600.
7
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.使用非选择性非甾体抗炎药或昔布类药物出现的严重下消化道临床事件。
Gastroenterology. 2003 Feb;124(2):288-92. doi: 10.1053/gast.2003.50054.
8
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.塞来昔布治疗骨关节炎和类风湿关节炎的疗效、耐受性及上消化道安全性：随机对照试验的系统评价
BMJ. 2002 Sep 21;325(7365):619. doi: 10.1136/bmj.325.7365.619.
9
COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.COX - 1和COX - 2、肠道完整性与小鼠非甾体抗炎药肠病的发病机制
Gastroenterology. 2002 Jun;122(7):1913-23. doi: 10.1053/gast.2002.33647.
10
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?选择性环氧化酶-2抑制剂是否优于传统非甾体抗炎药？
BMJ. 2002 Jun 1;324(7349):1287-8. doi: 10.1136/bmj.324.7349.1287.
Zotero 插件